The industry’s eyes are on whether the long-acting HIV combination therapy ‘Vocabria+Rekambys’ will be reimbursed by the end of the year in Korea.

According to industry sources, GSK Korea and Janssen Korea have completed the pharmacoeconomic evaluation of their HIV drugs Vocabria (cabotegravir) and Rekambys (rilpivirine) combination therapy and are awaiting the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee’s review.

It remains to be seen whether the drug will be reviewed by DREC by the end of the year and progress onward. As it has been more than 2 years since the drug’s domestic approval, the industry’s eyes are on whether it will